HC Wainwright Has Optimistic Outlook of INO Q1 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Inovio Pharmaceuticals in a report issued on Monday, March 16th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.34). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($1.05) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68. The business had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.33 million.

Other research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. Finally, Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.75.

Inovio Pharmaceuticals Price Performance

NASDAQ INO opened at $1.65 on Wednesday. The company has a 50 day simple moving average of $1.65 and a 200-day simple moving average of $2.03. The firm has a market capitalization of $114.00 million, a price-to-earnings ratio of -0.98 and a beta of 1.70. Inovio Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $2.98.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in INO. Boxer Capital Management LLC acquired a new stake in Inovio Pharmaceuticals in the third quarter valued at approximately $5,382,000. MCF Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth $26,000. SG Americas Securities LLC bought a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $27,000. Stephens Inc. AR bought a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $32,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals News Summary

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright nudged several 2026 quarterly estimates and raised its FY2026 EPS forecast slightly (to -$1.05), a modestly constructive read on the company’s outlook from an analyst who remains Neutral on the stock. Read More.
• Neutral Sentiment: Q4 2025 earnings call transcript posted — investors can review management commentary for detail on drivers behind recent results and guidance assumptions. Read More.
• Negative Sentiment: Multiple law firms have filed or announced class actions against Inovio and are soliciting lead-plaintiff applications, with an important April 7, 2026 deadline to seek lead-plaintiff status. The surge of filings and solicitor notices (Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, Schall, Pomerantz, Rosen, Faruqi & Faruqi, Levi & Korsinsky and others) increases legal risk, potential litigation costs and investor uncertainty—factors that often pressure biotech share prices. Representative notices: Read More. • Read More. • Read More.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.